CN100390164C - 异喹啉化合物及其医药用途 - Google Patents

异喹啉化合物及其医药用途 Download PDF

Info

Publication number
CN100390164C
CN100390164C CNB200380100827XA CN200380100827A CN100390164C CN 100390164 C CN100390164 C CN 100390164C CN B200380100827X A CNB200380100827X A CN B200380100827XA CN 200380100827 A CN200380100827 A CN 200380100827A CN 100390164 C CN100390164 C CN 100390164C
Authority
CN
China
Prior art keywords
isoquinoline
methyl
ketone
hydroxyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380100827XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1703410A (zh
Inventor
藤尾雅和
佐藤裕行
井上伸哉
松本寿史
江木康阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of CN1703410A publication Critical patent/CN1703410A/zh
Application granted granted Critical
Publication of CN100390164C publication Critical patent/CN100390164C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CNB200380100827XA 2002-10-01 2003-10-01 异喹啉化合物及其医药用途 Expired - Fee Related CN100390164C (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP288833/2002 2002-10-01
JP2002288833 2002-10-01
JP2002340175 2002-11-22
JP340175/2002 2002-11-22
JP109160/2003 2003-04-14
JP2003109160 2003-04-14
PCT/JP2003/012608 WO2004031171A1 (ja) 2002-10-01 2003-10-01 イソキノリン化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
CN1703410A CN1703410A (zh) 2005-11-30
CN100390164C true CN100390164C (zh) 2008-05-28

Family

ID=32074144

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200380100827XA Expired - Fee Related CN100390164C (zh) 2002-10-01 2003-10-01 异喹啉化合物及其医药用途

Country Status (12)

Country Link
US (3) US7220759B2 (enExample)
EP (1) EP1557414B1 (enExample)
JP (1) JP4520406B2 (enExample)
KR (1) KR100735781B1 (enExample)
CN (1) CN100390164C (enExample)
AT (1) ATE552252T1 (enExample)
CA (1) CA2500888C (enExample)
DK (1) DK1557414T3 (enExample)
ES (1) ES2380917T3 (enExample)
PT (1) PT1557414E (enExample)
TW (1) TW200424188A (enExample)
WO (1) WO2004031171A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1557414B1 (en) * 2002-10-01 2012-04-04 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
JP4567460B2 (ja) * 2002-11-22 2010-10-20 田辺三菱製薬株式会社 イソキノリン化合物及びその医薬用途
ES2514517T3 (es) 2007-08-10 2014-10-28 Mitsubishi Tanabe Pharma Corporation Nueva sal de compuesto de isoquinolina y cristal de la misma
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
WO2013004652A1 (de) 2011-07-04 2013-01-10 Bayer Intellectual Property Gmbh Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR102104144B1 (ko) * 2012-03-07 2020-04-23 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도
WO2015036759A1 (en) * 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AR098776A1 (es) * 2013-12-18 2016-06-15 Chiesi Farm Spa Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
AU2020376697B2 (en) * 2019-10-30 2024-03-14 Digmbio. Inc. Isoquinolinone derivative, preparation method therefor, and pharmaceutical composition, comprising same as active ingredient, for prevention or treatment of poly(ADP-ribose)polymerase-1 (PARP-1)-associated disease
CN113636970B (zh) * 2021-09-13 2023-05-23 河北康泰药业有限公司 一种异吲哚酮的化合物、制备方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4612454Y1 (enExample) * 1968-07-26 1971-04-30
WO1999011628A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhi biting parp activity
WO1999059973A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
CN1278797A (zh) * 1997-09-03 2001-01-03 吉尔福特药品有限公司 氧代化合物、其制备方法和组合物及抑制parp活性的方法
WO2002048117A1 (en) * 2000-12-11 2002-06-20 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1062357A (en) 1912-05-31 1913-05-20 Warschauer Schrauben Und Drahtfabriken Ag Nut-lock.
US1174272A (en) 1915-10-27 1916-03-07 Commw Steel Locomotive-bed.
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
DE2121031A1 (en) 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
IT1054655B (it) 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
JPS52156875A (en) 1976-06-23 1977-12-27 Mitsui Toatsu Chem Inc Preparation of novel isoquinolone derivatives
JPS5484597A (en) 1977-12-15 1979-07-05 Yamanouchi Pharmaceut Co Ltd Novel heterocyclic compound and its preparation
JPS6442472U (enExample) 1986-06-14 1989-03-14
US4808595A (en) 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
JPS6442472A (en) 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
CA1334969C (en) 1988-08-19 1995-03-28 Mark James Suto Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
AU2004200A (en) 1999-01-14 2000-08-01 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6677333B1 (en) 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JPWO2001079184A1 (ja) 2000-04-18 2004-03-18 住友製薬株式会社 置換ピペラジン類
WO2002044157A2 (en) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
EP1557414B1 (en) * 2002-10-01 2012-04-04 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
JP4567460B2 (ja) 2002-11-22 2010-10-20 田辺三菱製薬株式会社 イソキノリン化合物及びその医薬用途
JP4612454B2 (ja) 2005-03-31 2011-01-12 本田技研工業株式会社 ブレーキ制御装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4612454Y1 (enExample) * 1968-07-26 1971-04-30
WO1999011628A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhi biting parp activity
CN1278797A (zh) * 1997-09-03 2001-01-03 吉尔福特药品有限公司 氧代化合物、其制备方法和组合物及抑制parp活性的方法
WO1999059973A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
WO2002048117A1 (en) * 2000-12-11 2002-06-20 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives

Also Published As

Publication number Publication date
ATE552252T1 (de) 2012-04-15
WO2004031171A1 (ja) 2004-04-15
US20090076276A1 (en) 2009-03-19
EP1557414A4 (en) 2007-10-31
TWI338687B (enExample) 2011-03-11
CA2500888C (en) 2010-07-13
EP1557414A1 (en) 2005-07-27
KR20050070024A (ko) 2005-07-05
PT1557414E (pt) 2012-04-17
US20070161620A1 (en) 2007-07-12
KR100735781B1 (ko) 2007-07-06
US7459465B2 (en) 2008-12-02
US20040248931A1 (en) 2004-12-09
TW200424188A (en) 2004-11-16
CA2500888A1 (en) 2004-04-15
US7812178B2 (en) 2010-10-12
CN1703410A (zh) 2005-11-30
US7220759B2 (en) 2007-05-22
EP1557414B1 (en) 2012-04-04
ES2380917T3 (es) 2012-05-21
AU2003268724A1 (en) 2004-04-23
JPWO2004031171A1 (ja) 2006-02-02
JP4520406B2 (ja) 2010-08-04
DK1557414T3 (da) 2012-05-29

Similar Documents

Publication Publication Date Title
US7812178B2 (en) Isoquinoline compound and pharmaceutical use thereof
US20040176361A1 (en) Fused heterocyclic compound and medicinal use thereof
CA2507027C (en) Isoquinoline compounds and medicinal use thereof
AU2013296627C9 (en) Deuterated ibrutinib
KR19990081823A (ko) 카파 길항제 화합물 및 이들의 약제학적 제형
EA023962B1 (ru) Дейтерированные морфинановые соединения
TW200528109A (en) Method of treatment of atherosclerosis
TW201100385A (en) Substituted isoquinoline derivative
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
JP6929857B2 (ja) ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
EP1638934B1 (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
CN113993589A (zh) 新egfr抑制剂
RU2297411C2 (ru) Изохинолиновые соединения, промежуточные соединения, способы их получения и применение
WO2021174581A1 (zh) 吲唑类化合物的新用途
CN114751874A (zh) 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用
JP2003503479A (ja) Ｎ置換化グリシン誘導体
TW202339706A (zh) 含醯胺的ｌｏｎｐ１抑制劑化合物、用途及方法
HK40040558B (zh) 可用於治疗与中枢神经系统有关的疾病或病症的n-(杂)芳基-取代的杂环衍生物
JP2006282602A (ja) メラノコルチン−４受容体アゴニスト作用を有する新規ピペリジン誘導体
HK1081441B (zh) 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物
HK1081441A1 (zh) 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: TANADE SEIYAKU CO., LTD.

Free format text: FORMER OWNER: MITSUBISHI PHARMACEUTICAL CORP.

Effective date: 20080711

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TANABE MITSUBISHI PHARMACEUTICAL CO.

Free format text: FORMER NAME OR ADDRESS: TANADE SEIYAKU CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Osaka

Patentee after: MITSUBISHI TANABE PHARMA Corp.

Address before: Osaka

Patentee before: Tanabe Seiyaku Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20080711

Address after: Osaka

Patentee after: Tanabe Seiyaku Co.,Ltd.

Address before: Osaka

Patentee before: MITSUBISHI PHARMA Corp.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080528

Termination date: 20181001

CF01 Termination of patent right due to non-payment of annual fee